HC Wainwright & Co. Reiterates Buy on Absci, Maintains $16 Price Target
10/12/2026
Impact: 80
Healthcare
HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a Buy rating on Absci (NASDAQ: ABSI) and maintained a price target of $16 for the company's stock.
AI summary, not financial advice
Share: